Table 1 Patient and tumour characteristics

From: Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

No. of patients

26

Male/female

19/7

Median age, years (range)

52 (28–74)

Performance status (Karnofsky)

 

 100

2

 80/90

24

Primary tumour site

 

 Colorectal

5

 Oesophagus

5

 Soft-tissue sarcoma

4

 Lung

3

 Mesothelioma

2

 Others

7a

Prior treatment

 

 Surgery

26

 Radiotherapy

6

 Hormonal/biological

6

 Chemotherapy

25

Prior chemotherapy

 

 Median number of regimens (range)

2 (1–4)

 Previous anthracycline treatment

9

  1. aEwing's sarcoma (one), ovary (one), kidney (one), cholangiocarcinoma (one), liver (one), neuroblastoma (one), unknown primary (one).
Back to article page